Preclinical Capabilities

Optimal CAR-T Study Design to Advance Your Therapeutic Program.

Trusted immuno-oncology models.

TD2 is your trusted, experienced team when it comes to running preclinical Adoptive Cell Transfer Therapy studies. Our extensive knowledge of CAR-T in both solid and hematologic tumors enables optimal study design and rapid study initiation.

Not only can we execute your preclinical studies, but we provide a consultative approach to ensure best results and continuity with a clinical and regulatory strategy. Having performed more than 100 studies and strong experience with CAR T-cell handling and processing, we have the specialized oncology knowledge to design and execute your preclinical program in support of your clinical and regulatory goals.

TD2 can begin with cryopreserved or fresh CAR T-cells. We use fluorescent-based counting methods rather than manual dye counting to learn more about the viability of the CAR T-cells. Fluorescent counting helps to more accurately determine cell count and viability. See available cell lines

TD2 has been an extremely valuable and flexible partner for CRISPR Therapeutics, performing many CAR-T cell mouse studies across multiple antigen targets in a number of oncology indications.

• Dr. Jon TerrettHead of Immuno-Oncology Research and Translation CRISPR Therapeutics